Halogen-Substituted Phenyl Ether Compounds for THR-beta Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemical modifications of MGL-3196, a chloride-substituted phenyl ether compound, to improve its pharmacokinetic properties and agonistic activity as a thyroid hormone receptor β (THR-β) agonist are unpredictable and often result in undesirable changes, making it challenging to develop drugs with enhanced performance.
Innovation Solution
A series of halogen-substituted phenyl ether compounds with specific deuterium substitution sites and types are developed, which exhibit improved agonistic activity and selectivity for THR-β and THR-α, along with enhanced pharmacokinetic properties, by optimizing the structural modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical modification is performed to improve pharmacokinetic properties and agonistic activity, then drug performance may be enhanced, but the changes are unpredictable and may result in undesirable properties
Solution Approach 1:
The patent applies parameter changes by systematically modifying specific positions in the MGL-3196 molecular structure (positions 2, 4, 6 on the phenyl ring and positions 3, 5 on the pyridazinone ring) with halogen atoms (F, Cl, Br, I) and deuterium atoms. This structured approach to changing molecular parameters allows predictable improvement of pharmacokinetic properties and agonistic activity while avoiding unpredictable undesirable changes.
2Duration of action of moving object
If deuterium substitution is performed to prolong half-life, then C-D bond stability increases, but pharmacokinetic properties may become worse due to metabolic complexity
Solution Approach 1:
The patent applies local quality by selectively substituting deuterium atoms at specific positions (2, 4, 6 on phenyl ring and/or 3, 5 on pyridazinone ring) rather than uniform deuteration throughout the molecule. This localized approach allows the C-D bond stability to prolong half-life at specific metabolic sites while avoiding negative pharmacokinetic effects that might arise from deuteration at other positions.
Solution Approach 2:
The patent combines parameter changes by simultaneously modifying multiple molecular parameters: halogen substitution at specific ring positions, deuterium substitution at specific positions, and combination thereof. This multi-parameter approach systematically optimizes both half-life extension and pharmacokinetic properties, making the outcomes predictable rather than contingent.
3Reliability
If structural modification is performed to improve agonistic activity, then THR-β selectivity may be enhanced, but the complexity of modification increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular modification into distinct segments: halogen substitution at positions 2, 4, 6 of the phenyl ring; deuterium substitution at positions 2, 4, 6 of the phenyl ring and/or positions 3, 5 of the pyridazinone ring; and combination thereof. This segmented approach to structural modification simplifies the complexity by providing a systematic framework for improving agonistic activity and THR-β selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate significantly higher agonistic activity and selectivity for THR-β, along with improved pharmacokinetic properties, offering promising applications in treating dyslipidemia, hypercholesterolemia, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease.
Implementation Method 1
Deuterated drugs refer to the substitution of some hydrogen atoms in a drug molecule with deuterium. Since the shape and volume of deuterium are close to those of hydrogen in drug molecules, deuterated drugs can generally retain the biological activity and selectivity of the original drug. As the C-D bond is more stable than the C—H bond, the C-D bond of deuterated drugs is less likely to break during the chemical reaction, and thus the half-life may be prolonged.
Data Source
AI summary
A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.